🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Despite limited access due to CoVID-19, routine health maintenance is key. Several non-invasive options that can be done at home including Cologuard Mayo Clinic Comprehensive Cancer Center Mayo Clinic health.usnews.com/health-care/pa…

Agree 💯 %. Additionally, the clinical benefit for pembro is in a small subset of patients, with no biomarker available for selection. It could not beat placebo. If there were no other therapies available, one could argue. But with agents that beat placebo (Cabo, Rego, Ram) 🤦🏻‍♂️

After yest FDA ODAC mtg, hearing the argument that the lack of benefit in KN240 was that it was underpowered. Are we really justifying a drug with incremental benefit should be used bc placebo did too well/over performed? We can do better for our pts Tanios Bekaii-Saab, MD Vinay Prasad MD MPH

Can’t wait!

Register now! Tanios Bekaii-Saab, MD of Mayo Clinic AZ will chair our GI Malignancies IPC with LIVE Q&A on 6/16 at 630pm AZ Time. #oncliveIPC OncLive SOSS donnashort To learn more, register here: ow.ly/H4eG50EATuc

A not to miss conference in #Miami (with a virtual option)! Everything you need to know about #gastrointestinal #cancer ! Fantastic lineup of speakers and loads of fun learning .. Yelena Y. Janjigian MD Daniel Catenacci Kristen Ciombor Daniel Ahn Christina Wu Milind Javle Rachna Shroff, MD, MS, FASCO

Great work from Mansi Arora and collaborators, now leading to an approved IIT to open shortly across all three Mayo Clinic sites. Hopefully results will lead to a reconsideration for a NCI CTEP Coop study in the future! Mayo Clinic Comprehensive Cancer Center Cholangiocarcinoma Foundation Stacie Lindsey Eileen M O’Reilly

How did he drop that?!

Incidence of #cholangiocarcinoma are rising as second most prominent #hcc #rarecancersday says ⁦Daniel Ahn⁩ with chairs ⁦Anthony El-Khoueiry⁩ ⁦Rachna Shroff, MD, MS, FASCO⁩ ⁦ISGIO⁩ ⁦PER⁩ ⁦Mayo Clinic Comprehensive Cancer Center⁩ ⁦UC San Diego Health⁩ ⁦University of Arizona⁩

Great talk to learn in-person from KOLs and friends! Tanios Bekaii-Saab, MD

Yes, excited to have a good friend and even better physician join our group!!!We’re lucky to have Christina Wu

While not their in person, watching and supporting colleague and friend presenting exciting data with MRTX849. Never too early to start! Mayo Clinic Comprehensive Cancer Center Tanios Bekaii-Saab, MD #ascogi22

HIMALAYA. If D is non inferior to S, T+D similar to D, is T needed? “Is the juice (toxicities) worth the squeeze?” Or is it better than atezo/bev? For patients with a contraindication to anti-angiogenic therapy, D (or T+D 😬) would be an appropriate first-line therapy in HCC.

Open across the country at academic and community centers Mayo Clinic Comprehensive Cancer Center Academic & Community Cancer Research United

Our review highlighting tucatinib in HER-2 mCRC. Ongoing MOUNTANEER trial through Academic & Community Cancer Research United led by Tanios Bekaii-Saab, MD and John Strickler investigating its efficacy in mCRC Mayo Clinic Comprehensive Cancer Center tandfonline.com/doi/full/10.10…

Our editorial on A021501. Do we really need radiation in PDAC? Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer | Gastroenterology | JAMA Oncology | JAMA Network ⁦Mayo Clinic Comprehensive Cancer Center⁩ ⁦Tanios Bekaii-Saab, MD⁩ jamanetwork.com/journals/jamao…

It is time we started treating radiation as experimental therapy in pancreatic cancer and found a way to prove its utility. I still use it where I believe it helps--such things as clearing margins and getting people time off systemic therapy, but would be nice to prove benefit

Daniel Ahn Mudit Chowdhary, MD Matt Spraker Freddy E Escorcia (@freddyeescorcia elsewhere) chadi nabhan MD, MBA, FACP Mayo Clinic Comprehensive Cancer Center Ralph Weichselbaum Jeff Michalski Matthew Katz, MD 🇺🇸🟦 Michael Chuong Joseph Herman MD, MSc, MSHCM DocDaviesMD Krishan Jethwa Marsha Reyngold “Given that olaparib is expensive and relatively toxic, and in the absence of a clear survival benefit, it may be difficult to justify its use”

Thank you for the opportunity to speak at this event for this great endeavor! Tanios Bekaii-Saab, MD Mayo Clinic Comprehensive Cancer Center

NAPOLI-3 positive. Historical retrospective data suggests no difference in survival between FOLFIRINOX and gem abraxane. Maybe naliri isn’t the same as iri? Looking forward to see data. ⁦Tanios Bekaii-Saab, MD⁩ ipsen.com/us/blog/press-…